Extended Data Fig. 3: crRNA performance during mCARMEN RVP pre-clinical LOD evaluation. | Nature Medicine

Extended Data Fig. 3: crRNA performance during mCARMEN RVP pre-clinical LOD evaluation.

From: Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants

Extended Data Fig. 3

a, Fluorescence for 12 replicate testing of SARS-CoV-2 viral seed stock at 5,000, 2,500, 1,000, and 500 copies µl−1 spiked into negative patient specimens. All samples were background subtracted using NTC-amp as a negative control. Plus sign (+) represents negative sample calls by RVP results. b and e, Area under the receiver operating characteristic (AUROC) curve for crRNA detection. Blue bar represents the maximal AUROC time point at 1 hr post-reaction initiation c and f, Evaluation of sensitivity and specificity of crRNA detection to establish hit calling threshold. Black line: sensitivity/true positive rate; gray line: specificity/true negative rate; red line: hit calling threshold. d and g, Confusion matrix of expected vs predicted detection. b-d, SARS-CoV-2 crRNA detection only. e-g, all nine respiratory viruses on RVP.

Back to article page